Heartpoint Global Inc.
Miami, FL
- UEI
- PA71QLU96QM6
- CAGE
- 13RQ1
- Primary NAICS
- 339112 Surgical and Medical Instrument Manufacturing
- SAM.gov registration
- Active through
Company facts
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- SAM.gov registration date
- Physical address
- 1 Alhambra Plaza, Miami, FL 33134, USA
- Website
- heartpointglobal.com
- Founded
- 2014
- Employees
- 11-50
- Estimated annual revenue
- $1M-$10M
- Industry
-
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- Pharmaceuticals
- SIC code
- 80 Health Services
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Grant awards
| Award | Agency | Obligated | Awarded |
|---|---|---|---|
| Intellistent: a minimally invasive, adjustable pulmonary flow restrictor system for congenital and acquired heart… | National Heart Lung and Blood Institute (NIH) | $3,011,780 |
Grant subawards
| Prime recipient | Prime award | Amount | Awarded |
|---|---|---|---|
| Research Institute At Nationwide Children's Hospital | P50FD007961 | $75,000 | |
| The Regents Of The University Of California. San Francisco | P50FD007967 | $50,000 | |
| The Regents Of The University Of California. San Francisco | P50FD007967 | $25,000 |
Similar vendors
| Vendor | Location | Primary NAICS |
|---|---|---|
| Starlight Cardiovascular, Inc. | San Diego, CA | 339112 Surgical and Medical Instrument Manufacturing |
| Corvion, Inc. | Webster, TX | 334510 Electromedical and Electrotherapeutic Apparatus Manufacturing |
| Bivacor Inc. | Huntington Beach, CA | — |
| Annoviant, Inc. | Alpharetta, GA | 541714 Research and Development in Biotechnology (except Nanobiotechnology) |
| Bridgesource Medical, Corp. | Austin, TX | 541330 Engineering Services |
About the company
Heartpoint Global Inc., a for-profit medical device manufacturer based in Miami, Florida, is a federal grant recipient developing a minimally invasive pulmonary flow restrictor for pediatric and congenital heart disease treatment, operating primarily in a subcontractor role (75% of recent awards) across federal health research programs. The company holds one prime grant award and three sub-grants from the National Institutes of Health and its subordinate institutes, with combined obligated dollars of $1.9 million across four awards dating from June 2024 through March 2026.
Heartpoint's federal footprint centers on a single prime grant vehicle: a $1.77 million Project Grant from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), awarded September 1, 2025, running through August 31, 2027. The grant funds development and first-in-human clinical trial preparation for the INTELLISTENT system, a minimally invasive, adjustable pulmonary flow restrictor designed to treat neonatal and pediatric heart disease patients. Deliverables include downsizing the device from its current pediatric formulation (age 12+) to neonatal and infant sizes suitable from birth, completing biocompatibility testing required for FDA regulatory submission, and optimizing manufacturing processes for clinical and commercial production. Work is performed at Heartpoint's Coral Gables, Florida facility. As a sub-recipient, Heartpoint participates in the Midwest Pediatric Device Consortium (MPDC) administered by Nationwide Children's Hospital's Research Institute (sub-award dated March 31, 2026) and receives regulatory strategy and FDA pre-submission support from the University of California, San Francisco (sub-awards dated February 9, 2026 and June 24, 2024). The June 2024 sub-award specifically supported FDA pre-submission filing, first-in-human trial protocol development, and Breakthrough Device Program designation pursuit, with budgeted clinical research organization and regulatory consulting costs. One award faces ultimate completion inside the next twenty-four months and enters recompete window.
Quick answers
Is Heartpoint Global Inc. registered in SAM.gov?
Yes. Heartpoint Global Inc.'s SAM.gov registration is active through July 27, 2027.
What is Heartpoint Global Inc.'s CAGE code?
Heartpoint Global Inc.'s CAGE code is 13RQ1, and its Unique Entity ID (UEI) is PA71QLU96QM6.
What is Heartpoint Global Inc.'s most recent federal award?
Heartpoint Global Inc.'s most recent federal grant award is Intellistent: a minimally invasive, adjustable pulmonary flow restrictor system for congenital and acquired heart… (R44HL182590), from National Heart Lung and Blood Institute (NIH), on September 1, 2025.
On GovTribe
See Heartpoint Global Inc.'s full federal record
- Federal grant awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors